Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal, Open Label, Multi-Center, Safety and Pharmacokinetic Study of MB-102 (Relmapirazin) and the Use of the MediBeacon Transdermal GFR Measurement System in Normal and Renal Compromised Subjects for the Evaluation of Kidney Function

NCT05425719 is registered in ClinicalTrials.gov with MediBeacon as lead sponsor.

NCT NCT05425719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05425719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal, Open Label, Multi-Center, Safety and Pharmacokinetic Study of MB-102 (Relmapirazin) and the Use of the MediBeacon Transdermal GFR Measurement System in Normal and Renal Compromised Subjects for the Evaluation of Kidney Function
Lead sponsor
MediBeacon
Phase
Phase 3
Overall status
Completed
Start date
June 14, 2022
Completion date
February 15, 2023
Enrollment
249 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease